



international bowel
ULTRASOUND GROUP

IUS in IBD – State of Evidence in 2026

Bram Verstockt

University Hospitals Leuven, Belgium




Hamburg, Germany – September 19th, 2026

Disclosure

- Research support from AbbVie, Biora Therapeutics, Celltrion, Landos, Pfizer, Sanofi, Sosei Heptares/Nxera and Takeda.
- Speaker's fees from Abbvie, Agomab, Alfasigma, Biogen, Bristol Myers Squibb, Celltrion, Eli Lilly, Falk, Ferring, Galapagos, Materia Prima, Johnson and Johnson, Pfizer, Sandoz, Takeda, Tillots Pharma, Truvion and Viatrix.
- Consultancy fees from Abbvie, Agomab, Alfasigma, Alimentiv, Anaptys Bio, Applied Strategic, Astrazeneca, Atheneum, BenevolentAI, Biora Therapeutics, Boxer Capital, Bristol Myers Squibb, Domain Therapeutics, Eli Lilly, Galapagos, Guidepoint, Landos, Merck, Mirador Therapeutics, Mylan, Nxera, Inotrem, Ipsos, Johnson and Johnson, Onco3R, Pallisade Bio, Pfizer, Sandoz, Sanofi, Santa Ana Bio, Sapphire Therapeutics, Sosei Heptares, Takeda, Tillots Pharma and Viatrix.
- Stock options Vagustim and Thethis Pharma.

Intestinal ultrasound in IBD is “hot”



The emerging role of IUS in postoperative Crohn's



Early intestinal ultrasound and fecal calprotectin predict endoscopic recurrence after ileocecal resection in Crohn's disease: the INSIGHT study

Maarten Pruijt¹; Janssen, Reimer¹; De Voogd, Floris¹; Teichert, Christoph¹; Centritto, Andrea²; Madsen, Gorm Roager³; Wienecke, Susann⁴; Schops, Ganel⁵; Di Matteo, Carmen⁶; Dukwen, Helene⁴; Burisch, Johan³; Kucharzik, Torsten⁷; Maaser, Christian⁷; Helwig, Ulf⁴; D'Haens, Geert¹; Allocca, Mariangela⁶; Petersen, Frauke⁷; Christensen, Britt⁸; Irving, Peter M.²; Verstockt, Bram⁵; Gecse, Krisztina¹

1. Department of Gastroenterology and Hepatology, Amsterdam UMC Locatie VUmc, Amsterdam, NH, Netherlands.

2. Guy's and St Thomas' NHS Foundation Trust Gastroenterology and Hepatology Service, London, England, United Kingdom.

3. Hvidovre Hospital, Hvidovre, Capital Region of Denmark, Denmark.

4. Klinikum Oldenburg AoR, Oldenburg, NDS, Germany.

5. UZ Leuven, Leuven, Flanders, Belgium.

6. IRCCS Ospedale San Raffaele, Milan, Lombardy, Italy.

7. Städtisches Klinikum Lüneburg gGmbH, Lüneburg, NDS, Germany.

8. The Royal Melbourne Hospital Department of Gastroenterology, Parkville, VIC, Australia.


IUS as a core monitoring tool in IBD

ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1


Part 1: initial diagnosis, monitoring of known inflammatory bowel disease, detection of complications

Torsten Kucharzik^{1,*}, Stuart Taylor², Mariangela Allocca³, Johan Burisch^{4,5,6}, Pierre Ellul⁷, Marietta Iacucci⁸, Christian Maaser⁹, Pamela Baldin¹⁰, Gauraang Bhatnagar¹¹, Shomron Ben-Horin¹², Dominik Bettenworth¹³, Mallory Chavannes¹⁴, Ann Driessen¹⁵, Emma Flanagan¹⁶, Frederica Furfaro¹⁷, Giovanni Maconi¹⁸, Konstaninos Karmiris¹⁹, Amelia Kellar^{20,21}, Isabelle De Kock²², Konstantinos Katsanos²³, Uri Kopylov²⁴, Cathy Lu²⁵, Olga Maria Nardone²⁶, Nurulamin M Noor²⁷, Kerri Novak²⁸, Paula Borralho Nunes²⁹, Patrick van Rheenen³⁰, Jordi Rimola³¹, Francesca Rosini³², David Rubin³³, Martina Scharitzer³⁴, Jaap Stoker^{35,36}, Mathieu Uzzan³⁷, Stephan Vavricka³⁸, Bram Verstockt³⁹, Rune Wilkens⁴⁰, Nina Zidar⁴¹, Alessandra Zilli⁴², Henit Yanai^{43,44}, Roger Feakins^{45,46}; on behalf of the European Crohn's and Colitis Organisation (ECCO), the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the European Society of Pathology (ESP), and the International Bowel Ultrasonography Group (IBUS)


IUS as a core monitoring tool in CD




IUS finding its way into clinical trials





IUS finding its way into clinical trials




IUS as a core monitoring tool in UC



IUS in the context of ASUC




IUS in UC : scratching below the surface!




IUS in UC : scratching below the surface!



Ultrasound image of the sigmoid of a patient with chronic, therapy-refractory ulcerative colitis




- Ultrasound aspects beyond the mucosa:
- Thickened submucosa
 - Loss of haustrations
 - Mesenteric fibrofatty proliferation
 - Loss of bowel wall stratification
 - Increased bowel wall thickness




Endoscopy:
• Mayo endoscopic subscore 3

Transmural biopsy of a patient with chronic, therapy-refractory ulcerative colitis




Submucosal fibrosis and increased fat cell deposition



- Histopathology:
- Thickened muscularis mucosae
 - Submucosal fibrosis
 - Muscular remodelling and fibrotic shifts
 - Increased fat cell deposition

Moving beyond SMT towards 'submucosal brightness'

Submucosal Hyper-echogenicity On Intestinal Ultrasound Is Associated With Fat Deposition And Predicts Treatment Non-response In Patients With Ulcerative Colitis



June 1st and 2nd 2027, Leuven, Belgium



IBUS Global Summit:
Non-invasive monitoring in IBD



international bowel
ULTRASOUND GROUP